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Introduction
Uterine myomas represent the most common benign
tumors of the female reproductive system [1,2]. They are
mostly asymptomatic [3], and expectant management
is, therefore, a common choice [4]. Some myomas,
however, can cause symptoms and require treatment
[5,6]. For women who wish to retain their childbearing
potential, organ-preserving strategies, such as myo-
mectomy, uterine artery ligation or embolization, focal
ultrasound surgery, or various kinds of medical treat-
ment, have been the preferred treatments [7–12]. Hys-
terectomy is still considered to be the treatment of
choice in women with symptomatic uterine myomas
who have completed their child bearing [13]. However,
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SUMMARY
Objective: To determine the acceptability and effectiveness of a gonadotropin-releasing hormone (GnRH) agonist
for the treatment of perimenopausal women with symptomatic uterine myomas.
Materials and Methods: The participants included 43 women with symptomatic myomas who wished to retain
their uteri. All the women were older than 45 years old, agreed to use the GnRH agonist for menopause induc-
tion, and were without any underlying malignancy. They were treated with six courses of GnRH agonist between
2004 and 2005. The definition of re-intervention included: (1) surgical intervention, such as hysterectomy,
myomectomy or laparoscopic uterine vessel occlusion, or (2) modification of GnRH agonist use. Modification
of GnRH agonist use included either failure to complete a 6-month GnRH agonist treatment course, or re-use
of GnRH agonist with/without interruption of continuity. Failure was defined as women who underwent surgi-
cal intervention or failed to complete the 6-month GnRH agonist treatment. Evaluations were performed every
6 months, for up to 2 years.
Results: Re-intervention rates were 14.0% (n = 6), 23.3% (n = 10) and 32.6% (n = 14), and failure rates were 
7.0% (n = 3), 11.6% (n = 5) and 16.3% (n = 7), at the end of the 6-, 12- and 24-month follow-up periods, respec-
tively. Three patients failed to complete the 6-month GnRH agonist treatment, and four received surgical 
interventions.
Conclusion: More than 80% of women in this study benefited from the use of GnRH agonist to produce
menopause, suggesting that this can be an alternative choice for managing perimenopausal women with 
symptomatic uterine myomas. [Taiwan J Obstet Gynecol 2009;48(2):133–137]
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the uterus has been psychologically regarded as a 
regulator and controller of important physiologic func-
tions, a sexual organ, a source of energy and vitality,
and a maintainer of youth and attractiveness [14].
Reproductive sex hormones such as estrogen and
progesterone appear to be critical factors related to
uterine myomas. Evidence for this includes the fact
that: (1) myomas are rarely observed before puberty;
(2) they are most prevalent during the reproductive
years, and regress after menopause; and (3) factors
that increase overall lifetime exposure to estrogen, such
as obesity and early menarche, increase the incidence
of myomas [15]. This provides us with the possibility
of manipulating sex hormones when treating women
with symptomatic uterine myomas. However, because
the effects of medical treatment are often transient
[15] and the symptoms and tumor frequently recur
after medication is stopped [16], the use of medical
treatment for symptomatic uterine myomas is limited
[17,18].
Although medical treatment is seldom considered
a definitive treatment, it may be beneficial in a given
population; women who are near menopausal status
(age ≥ 45 years, defined as perimenopausal) with symp-
tomatic uterine myomas might gain from medical treat-
ment [19,20]. Many drugs are currently available for
the management of symptomatic uterine myomas, in-
cluding gonadotropin-releasing hormone (GnRH) ago-
nists, GnRH antagonists, the progesterone-mediated
intrauterine system, selective estrogen receptor mod-
ulators, selective progesterone receptor modulators,
androgen-mediated therapy, growth factor-mediated
therapy, and others [15]. Among these medical treat-
ments, the use of GnRH agonists is possibly one of 
the best choices. Some perimenopausal women might
transit to natural menopause in an unexpectedly short
period, and the use of a GnRH agonist, leading to a
natural menopause, is a rational choice. In this study,
we explored the effectiveness and limitations of a GnRH
agonist for the management of perimenopausal women
with symptomatic uterine myomas.
Materials and Methods
Between January 2004 and December 2005, women
with symptomatic uterine myomas scheduled for uterine-
sparing treatment were invited to participate in the
present study. All the uterine-sparing treatments used
for symptomatic uterine myomas were well-accepted
procedures in our hospital. They included myomec-
tomy (performed by traditional exploratory laparotomy,
mini-laparotomy, ultramini-laparotomy, laparoscopy
or hysteroscopy), laparoscopic uterine vessel occlusion
(LUVO), combination therapy, and medical treatment,
including GnRH agonists, progestins, nonsteroidal anti-
inflammatory drugs, or pure consultation and follow-
up [5,6,10–12,15]. All patients had uterine fibroids
with symptoms comprising either menstrual problems,
such as menorrhagia and pain, or compression syn-
drome, including a bulge-like sensation and frequency.
These women were informed that they could choose 
to be treated with any one of the above-mentioned
procedures, based on their preference.
This study was designed to assess the effectiveness
and limitation of a GnRH agonist for the treatment of
fibroids in older women (age ≥ 45 years). Inclusion cri-
teria were: agreeing to use a GnRH agonist for meno-
pause induction for at least 6 months without surgical
intervention, no underlying malignancy, an initial strong
willingness to avoid surgical treatment if possible, and
commitment to completing a thorough, 2-year follow-
up record. Surgical interventions included hysterectomy,
myomectomy, LUVO or uterine artery embolization. 
A total of 43 patients were included, and all of them
received monthly treatment with a depot GnRH agonist
(leuprorelin; Leuplin-Depot; Takeda Pharmaceuticals,
Osaka, Japan).
Leiomyoma-related symptoms, including either men-
strual problems such as menorrhagia and pain, or com-
pression syndrome (including a bulge-like sensation
and frequency), were assessed using a five-point scale
to rate changes in symptoms relative to baseline. An
initial score of 3 was given if the symptom was present
in these women, and subsequent scores ranged from 
1 (marked exacerbation), 2 (slight exacerbation), 3
(consistent with the baseline), 4 (slight improvement),
to 5 (significant improvement). The same five-point
scale was also used to record satisfaction with a base-
line score of 3, and ranging from 1 (very dissatisfied)
to 5 (very satisfied).
At each follow-up evaluation (6, 12 and 24 months),
any medical or surgical treatment of the myoma was
recorded. Re-intervention included: (1) failure, defined
by the need for hysterectomy, myomectomy, uterine ves-
sel occlusion for uterine myomas, or discontinuation
of GnRH agonist treatment (treatment for < six cycles)
due to poor patient compliance; and (2) fulfillment of
the criteria of success, such as re-use of GnRH agonist
after completing the 6-month GnRH agonist treatment,
and continuous use of GnRH agonist for 24 months
without cessation.
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA)
was used to analyze patient data. Paired t tests were
used to analyze changes in each score from baseline.
Statistical significance was defined as p < 0.05.
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Results
The mean age of the patients was 47.4 ± 1.9 years. 
The mean baseline hemoglobin level was 9.2 ± 1.9 g/dL.
Additional baseline characteristics are provided in
Table 1.
In this study, continuous vaginal spotting was
noted in > 50% of the women (n = 24) after the first
dose of GnRH agonist. However, after the second dose
(1 month later), the incidence of continuous vaginal
spotting had decreased to 21% (n = 9), and after the
third dose, nearly all women had amenorrhea (98%, 
n = 42). Three patients (7%) stopped GnRH agonist
treatment after the third dose owing to intolerable or
severe climacteric symptoms. Although additional hor-
mone supplements were prescribed at the second dose
of GnRH agonist, these patients decided to stop any
further treatment. Finally, all women had amenorrhea
by the sixth dose when they continued with GnRH 
agonist treatment during the study period.
The re-intervention rate was 14% (n = 6) at the end
of the 6-month follow-up, including three patients who
failed to complete the 6-month GnRH agonist treat-
ment, and three patients who continued to receive
GnRH agonist monthly treatment after the 6-month
period. The re-intervention rate increased to 23.3% (n =
10) at the end of the 12-month follow-up. This in-
cluded the above-mentioned patients (n = 6), as well as
two patients who were treated with re-administration
of the GnRH agonist, one who underwent LUVO, and
one who underwent myomectomy. At the end of the
24-month follow-up, the re-intervention rate was 32.6%
(n = 14). This included the previous patients, plus a
further two who were re-administered GnRH agonist,
and two who underwent hysterectomy. The symptom
change and satisfaction scores improved significantly
between the successive 6-month follow-ups (at the
end of 6, 12 and 24 months) and baseline (p = 0.001),
suggesting that the women who were treated with the
GnRH agonist benefited from symptom improvement,
with a resultant high level of satisfaction. A summary
of the clinical outcomes is presented in Table 2.
Discussion
GnRH agonists are among the most effective and 
well-accepted drugs for the management of myomas.
They are analogs of endogenous GnRH and bind to
pituitary GnRH receptors (GnRH-R), resulting in the
synthesis and release of luteinizing hormone and 
follicle-stimulating hormone. Compared with GnRH,
GnRH agonists have a longer half-life, leading to con-
tinuous exposure of GnRH-R under the activity of GnRH
agonists. Downregulation of the GnRH-R consequently
results in a decreased level of gonadotropin and a 
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Table 2. Characteristics of subjects (n = 43) during follow-up*
Follow-up
Baseline 6 months 12 months 24 months
Re-intervention 0 (0) 6 (14) 10 (23.3) 14 (32.6)
Hemoglobin level (g/dL) 9.16 ± 2.18 12.87 ± 0.55 11.22 ± 0.22 11.16 ± 0.27
Symptom†
Pain 0.56 ± 1.18 0.91 ± 0.29‡ 0.81 ± 0.26‡ 0.79 ± 0.26‡
Menorrhagia 2.09 ± 1.39 3.49 ± 0.35‡ 2.74 ± 0.21‡ 2.88 ± 0.34‡
Bulge sensation 1.19 ± 1.48 1.81 ± 0.35‡ 1.65 ± 0.32‡ 1.60 ± 0.32‡
Frequency 1.05 ± 1.45 1.58 ± 0.39‡ 1.47 ± 0.32‡ 1.44 ± 0.32‡
Amenorrhea 0 (0) 40 (93.0) 14 (32.5) 20 (46.5)
Satisfaction† 3.00 ± 0.00 4.44 ± 0.73‡ 4.12 ± 0.96‡ 4.28 ± 0.98‡
Failure 3 (7.0) 5 (11.6) 7 (16.3)
*Data are presented as n (%) or mean ± standard deviation; †the definitions of symptom (pain, menorrhagia, bulge sensation, frequency) change and satisfaction
are available in the text; ‡compared with baseline, all p < 0.005.
Table 1. Clinical characteristics of the patients (n = 43)*
Age (yr) 47.4 ± 1.9
Body mass index 22.46 ± 1.56




Bulge sensation 17 (39.5)
Frequency 15 (34.9)
*Data are presented as mean ± standard deviation or n (%).
suppressed production of ovarian hormones [21]. The
administration of GnRH agonists leads to extremely
low “pseudomenopausal” or “pseudopremenarchal”
estradiol levels, resulting in amenorrhea. 
In terms of alleviating menorrhagia, it has been re-
ported that bleeding problems or related anemia were
controlled in women after the first month of GnRH
agonist treatment [22,23].
Pain and pressure symptoms were reported to 
be relieved within the first 3 months of treatment. This
effect can be achieved within the first 12 weeks of 
therapy, because it is considered to be a consequence
of reducing the size of the uterus and myoma [24]. In
addition, it has been reported that the effect of GnRH
agonists on reducing myoma size is transient; reversal of
estrogen deprivation occurs about 4 weeks after discon-
tinuation of the GnRH agonist [25] and most myoma
nodules returned to their initial size within about 6
months after discontinuation of treatment. The rate 
of enlargement was then rapid compared with natural
enlargement [22], and regrowth of the uterus and
myomas leads to a recurrence of the initial symptoms
[26]. We did not routinely monitor uterine and myoma
size in the current study, so were unable to assess any
changes. However, all but three of the women (who
failed to complete the 6-month GnRH agonist treat-
ment) were satisfied with their symptom relief, includ-
ing pain, bulging sensation and frequency, especially
after the initial 6 months. The symptom improvement
was maintained up to the end of the 12- and 24-month
follow-ups (Table 2), suggesting that the use of GnRH
agonist treatment for perimenopausal women with
symptomatic uterine myomas should be considered
before choosing a more invasive surgical intervention.
The significant disadvantages of GnRH agonists in-
clude hypoestrogenism-related effects resembling post-
menopausal climacteric disturbances and bone loss [27].
Partial restoration of the estrogenic state by reduced-
dose therapy or steroid “add-back” has been shown to
be effective for the relief of annoying side effects, with-
out any loss of the beneficial effects on myoma size
and cycle suppression [28,29]. The addition of oral
veralipride, a benzamide derivative, can reduce the
vasomotor symptoms induced by GnRH agonists [30].
Raloxifene or tibolone may also be used as add-back
therapy to prevent bone loss whilst preserving the effi-
cacy of GnRH agonists [31,32]. However, raloxifene
did not reduce vasomotor symptoms related to GnRH
agonists [31], and could even exacerbate climacteric
symptoms [33,34]. In contrast, a significant reduction
in hot flushes was observed when tibolone was added
to GnRH agonist treatment [32]. Either a lower dose
of hormone replacement therapy or use of tibolone
can be successfully applied in symptomatic menopausal
women [35–39]. In this study, only three women who
failed to complete the 6-month GnRH agonist treat-
ment were reported to have intolerable climacteric
symptoms. Although add-back therapy was initiated
during the third month, the patients were still anxious
about the risk of breast cancer and finally decided 
to stop any medication, except for nonsteroidal anti-
inflammatory drugs and iron replacement. In contrast,
more than 90% of the perimenopausal women tolerated
the treatment well. In addition, three women chose to
continue monthly GnRH agonist treatment up to 24
months and two women were re-treated with GnRH
agonist 12 months later.
Amenorrhea was reported in only 50% of the
women in this study, at the end of the 24-month follow-
up period. This was in contrast to the results of Imai 
et al [19], who found that the depot GnRH agonist,
leuprorelin acetate, produced an excellent success rate
(> 90%) by inducing natural menopause in 19 of 21
perimenopausal women with uterine myomas [19].
In conclusion, more than 80% of women in this
study experienced significant symptom relief after treat-
ment with a GnRH agonist. These results indicate that
GnRH agonists should be considered as an option for
the management of perimenopausal women with uter-
ine myomas, in order to reduce the use of more invasive
surgical interventions.
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